Key Points
- Insider sale: Director David Michael Clark sold 25,642 shares at an average price of $14.17 on Dec. 19 (SEC filing), trimming his stake by 9.45% for a $363,347 transaction.
- Report that BioMarin agreed to acquire Amicus for roughly $4.8 billion — a confirmed deal would likely push FOLD materially higher for shareholders.
- Several brokers (Citigroup, TD Cowen, Cantor Fitzgerald) have downgraded FOLD to "hold," leaving a MarketBeat consensus of Hold and an average price target near $15.81, which offsets recent technical strength.
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) insider David Michael Clark sold 25,642 shares of the firm's stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $14.17, for a total transaction of $363,347.14. Following the transaction, the insider directly owned 245,690 shares in the company, valued at $3,481,427.30. This trade represents a 9.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
David Michael Clark also recently made the following trade(s):
- On Monday, December 15th, David Michael Clark sold 25,643 shares of Amicus Therapeutics stock. The stock was sold at an average price of $11.00, for a total transaction of $282,073.00.
- On Monday, November 24th, David Michael Clark sold 25,643 shares of Amicus Therapeutics stock. The shares were sold at an average price of $10.10, for a total transaction of $258,994.30.
- On Tuesday, November 4th, David Michael Clark sold 25,643 shares of Amicus Therapeutics stock. The stock was sold at an average price of $9.51, for a total transaction of $243,864.93.
Amicus Therapeutics Price Performance
Amicus Therapeutics stock opened at $14.21 on Wednesday. The company has a quick ratio of 2.09, a current ratio of 2.99 and a debt-to-equity ratio of 1.70. The firm has a market cap of $4.38 billion, a P/E ratio of -355.16 and a beta of 0.46. The business has a fifty day moving average of $9.72 and a two-hundred day moving average of $7.96. Amicus Therapeutics, Inc. has a twelve month low of $5.51 and a twelve month high of $14.36.
Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.12 by $0.05. The firm had revenue of $169.06 million during the quarter, compared to analyst estimates of $165.24 million. Amicus Therapeutics had a positive return on equity of 6.95% and a negative net margin of 2.35%.The business's revenue for the quarter was up 19.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.10 EPS. On average, analysts forecast that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the company. Norges Bank purchased a new position in Amicus Therapeutics during the 2nd quarter worth approximately $18,540,000. Jump Financial LLC boosted its holdings in shares of Amicus Therapeutics by 246.3% in the 2nd quarter. Jump Financial LLC now owns 1,406,563 shares of the biopharmaceutical company's stock valued at $8,060,000 after acquiring an additional 1,000,395 shares during the last quarter. Capital Fund Management S.A. increased its stake in shares of Amicus Therapeutics by 408.8% in the first quarter. Capital Fund Management S.A. now owns 312,561 shares of the biopharmaceutical company's stock worth $2,550,000 after acquiring an additional 251,134 shares during the period. Advantage Alpha Capital Partners LP purchased a new position in shares of Amicus Therapeutics during the second quarter worth $201,000. Finally, 683 Capital Management LLC lifted its position in Amicus Therapeutics by 249.1% during the second quarter. 683 Capital Management LLC now owns 960,000 shares of the biopharmaceutical company's stock valued at $5,501,000 after purchasing an additional 685,000 shares during the period.
Amicus Therapeutics News Summary
Here are the key news stories impacting Amicus Therapeutics this week:
- Positive Sentiment: Report that BioMarin agreed to acquire Amicus for roughly $4.8 billion — this is a direct, highly constructive development for shareholders because an acquisition at a premium would likely push FOLD materially higher. A $4.8 Billion Reason to Buy BioMarin Stock Today
- Positive Sentiment: Technical/market-interest signal: Amicus cleared a key benchmark and hit a 90-plus relative strength (RS) rating — a sign of strong recent price performance and institutional interest that can support further inflows. Amicus Therapeutics clears key benchmark, hitting 90-plus RS rating
- Neutral Sentiment: Citigroup has a neutral rating on FOLD with a $14.50 price target (down from $17.00) — this trims upside in broker guidance but is not an outright sell signal. Benzinga coverage
- Negative Sentiment: Citigroup downgraded Amicus from "strong-buy" to "hold" — an influential shop trimming its view can weigh on momentum and sentiment. Citigroup downgrades Amicus Therapeutics (FOLD)
- Negative Sentiment: TD Cowen cut its rating from buy to hold and set a $14.50 target — another downgrade that reduces broker-driven buying pressure. Finviz / TD Cowen note
- Negative Sentiment: Insider selling: director David Michael Clark sold 25,642 shares at about $14.17 (disclosed in an SEC filing) — insider sales can be interpreted by some investors as a signal of reduced insider conviction or portfolio rebalancing, which may add short-term selling pressure. SEC filing - insider sale
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on FOLD shares. Cantor Fitzgerald cut shares of Amicus Therapeutics from an "overweight" rating to a "hold" rating and lowered their price target for the company from $21.00 to $14.50 in a report on Friday, December 19th. The Goldman Sachs Group increased their target price on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the company a "neutral" rating in a research report on Wednesday, November 5th. TD Cowen downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating and set a $14.50 target price for the company. in a research note on Monday. Citigroup reaffirmed a "neutral" rating and issued a $14.50 price target (down from $17.00) on shares of Amicus Therapeutics in a report on Monday. Finally, Wall Street Zen upgraded Amicus Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Saturday, November 8th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $15.81.
Get Our Latest Stock Report on FOLD
About Amicus Therapeutics
(
Get Free Report)
Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.
The company's lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
